Fecal Microbiota Transplant Mitigates Adverse Outcomes Seen in Patients Colonized With Multidrug-Resistant Organisms Undergoing Allogeneic Hematopoietic Cell Transplantation
Authors:
Open Access
- 27 August 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 11, 684659
Abstract
The gut microbiome can be adversely affected by chemotherapy and antibiotics prior to hematopoietic cell transplantation (HCT). This affects graft success and increases susceptibility to multidrug-resistant organism (MDRO) colonization and infection. We performed an initial retrospective analysis of our use of fecal microbiota transplantation (FMT) from healthy donors as therapy for MDRO-colonized patients with hematological malignancy. FMT was performed on eight MDRO-colonized patients pre-HCT (FMT-MDRO group), and outcomes compared with 11 MDRO colonized HCT patients from the same period. At 12 months, survival was significantly higher in the FMT-MDRO group (70% versus 36% p = 0.044). Post-HCT, fewer FMT-MDRO patients required intensive care (0% versus 46%, P = 0.045) or experienced fever (0.29 versus 0.11 days, P = 0.027). Intestinal MDRO decolonization occurred in 25% of FMT-MDRO patients versus 11% non-FMT MDRO patients. Despite the significant differences and statistically comparable patient/transplant characteristics, as the sample size was small, a matched-pair analysis between both groups to non-MDRO colonized control cohorts (2:1 matching) was performed. At 12 months, the MDRO group who did not have an FMT had significantly lower survival (36.4% versus 61.9% respectively, p=0.012), and higher non relapse mortality (NRM; 60.2% versus 16.7% respectively, p=0.009) than their paired non-MDRO-colonized cohort. Conversely, there was no difference in survival (70% versus 43.4%, p=0.14) or NRM (12.5% versus 31.2% respectively, p=0.24) between the FMT-MDRO group and their paired non-MDRO cohort. Collectively, these data suggest that negative clinical outcomes, including mortality associated with MDRO colonization, may be ameliorated by pre-HCT FMT, even in the absence of intestinal MDRO decolonization. Further work is needed to explore this observed benefit.Keywords
Funding Information
- NIHR Imperial Biomedical Research Centre
- Medical Research Council
This publication has 46 references indexed in Scilit:
- Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignanciesJournal of Infection, 2016
- Impact of Gut Colonization by Antibiotic-Resistant Bacteria on the Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective, Single-Center StudyTransplantation and Cellular Therapy, 2016
- Chemotherapy‐driven dysbiosis in the intestinal microbiomeAlimentary Pharmacology & Therapeutics, 2015
- Microbiome manipulation with faecal microbiome transplantation as a therapeutic strategy in Clostridium difficile infectionQJM: An International Journal of Medicine, 2014
- Role of the Microbiota in Immunity and InflammationCell, 2014
- Control of pathogens and pathobionts by the gut microbiotaNature Immunology, 2013
- Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstreamEuropean Journal of Clinical Microbiology & Infectious Diseases, 2013
- Duodenal Infusion of Donor Feces for RecurrentClostridium difficileNew England Journal of Medicine, 2013
- Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phaseBlood, 2010
- Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell TransplantationTransplantation and Cellular Therapy, 2008